Novavax, Inc.
NVAX
$10.73
$0.656.40%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.12B | 1.06B | 1.08B | 1.25B | 682.16M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.12B | 1.06B | 1.08B | 1.25B | 682.16M |
| Cost of Revenue | 408.94M | 445.18M | 475.01M | 534.19M | 581.42M |
| Gross Profit | 714.54M | 619.47M | 603.71M | 720.78M | 100.74M |
| SG&A Expenses | 137.23M | 181.78M | 216.46M | 277.10M | 311.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 560.24M | 647.83M | 712.33M | 832.15M | 914.09M |
| Operating Income | 563.24M | 416.82M | 366.39M | 422.81M | -231.93M |
| Income Before Tax | 442.17M | 350.68M | 431.39M | 488.52M | -176.62M |
| Income Tax Expenses | 1.87M | 8.94M | 8.56M | 9.82M | 10.88M |
| Earnings from Continuing Operations | 440.30 | 341.75 | 422.82 | 478.70 | -187.50 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 440.30M | 341.75M | 422.82M | 478.70M | -187.50M |
| EBIT | 563.24M | 416.82M | 366.39M | 422.81M | -231.93M |
| EBITDA | 590.85M | 451.83M | 407.51M | 467.50M | -183.44M |
| EPS Basic | 2.74 | 2.13 | 2.61 | 3.05 | -1.22 |
| Normalized Basic EPS | 2.24 | 1.67 | 1.50 | 1.79 | -0.85 |
| EPS Diluted | 2.41 | 1.79 | 2.28 | 2.66 | -1.33 |
| Normalized Diluted EPS | 2.01 | 1.45 | 1.28 | 1.53 | -0.93 |
| Average Basic Shares Outstanding | 647.95M | 645.66M | 643.36M | 629.72M | 608.59M |
| Average Diluted Shares Outstanding | 682.38M | 677.43M | 675.13M | 663.77M | 626.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |